Pulse Biosciences (PLSE) Gross Margin (2021 - 2025)

Pulse Biosciences' (PLSE) quarterly Gross Margin came in at 224.42% in Q3 2025, up 44.88% quarter-over-quarter from 407.17% in Q2 2022.

Pulse Biosciences (PLSE) Gross Margin (2021 - 2025) Analysis & Trends

Pulse Biosciences' Gross Margin history runs 3 years deep, the most recent figure standing at 224.42% for Q3 2025.

On a quarterly basis, Gross Margin changed N/A year-over-year to 224.42% in Q3 2025; TTM through Sep 2025 was 224.42%, a N/A change from a year earlier, with the FY2022 full-year figure at 1606.29%, down 156571.0% from the prior year.
Gross Margin grew to 224.42% in Q3 2025 per PLSE's latest filing, from 407.17% in the prior quarter.
Across five years, Gross Margin topped out at 26.66% in Q3 2021 and bottomed at 407.17% in Q2 2022.
The 3-year median for Gross Margin is 104.73% (2022), against an average of 162.64%.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Alcon	32,734,969.19 Bn	32,734,967.53 Bn	1.53 Bn	56.80%
2	Intuitive Surgical	117.50 Bn	112.41 Bn	1.96 Bn	67.78%
3	Becton Dickinson	42.93 Bn	42.11 Bn	2.15 Bn	45.69%
4	Medline	30.82 Bn	36.66 Bn	1.84 Bn	25.04%
5	Resmed	27.90 Bn	26.23 Bn	890.98 Mn	62.25%
6	West Pharmaceutical Services	26.76 Bn	26.23 Bn	329.20 Mn	37.74%
7	Cooper Companies	15.30 Bn	15.16 Bn	735.40 Mn	68.00%
8	Solventum	13.46 Bn	12.90 Bn	1.10 Bn	54.66%
9	Align Technology	12.02 Bn	10.96 Bn	736.59 Mn	70.82%
10	Pulse Biosciences	2.09 Bn	2.01 Bn	-	-

Download Data